Cantargia builds power
(Thomson Reuters ONE) -
Cantargia is developing a new therapy aimed at removing leukemic stem cells in
CML patients and resulting in a permanent cure. The company has now secured
financing up to the pre-clinical phase, strengthened the Board, and recruited a
CEO.
LU Bio has invested SEK 5.8 million in Cantargia and now holds a 52 % stake in
the company, with the remainder held by the founders.
Cantargia has recruited Agneta Svedberg as CEO. Agneta most recently held a
Senior Advisor position at Semcon. She has extensive experience in antibody drug
development having worked for ten years as a member of the R&D management team
and lately also in the senior management team at Genmab A/S.
Mats Strömqvist, CEO of Omniohealer AB, serves as Cantargia's Chairman of the
Board. New board member Olof Tydén has clinical and regulatory experience from
the international pharmaceutical industry and expertise within hematology.
"Each one of the newly recruited members of the Cantargia team has the
particular experience and expertise we've been looking for to drive and shepherd
the development of the company" says Thomas Andersson, CEO of LU Bioscience AB.
"We couldn't be happier to have Agneta Svedberg, Mats Strömqvist, and Olof Tydén
on board."
Cantargia is developing a new therapy for hematologic malignancies (leukemia).
The conceptually new approach has been validated ex vivo with patient-derived
leukemic stem cells. The project is based on the original discovery that certain
leukemic cells in patients with chronic myeloid leukemia (CML) express a cell-
surface receptor, the Interleukin-1 receptor accessory protein (IL1RAP), whereas
corresponding normal hematopoietic stem cells do not express this receptor.
Cantargia uses this receptor as the target for development of a novel antibody-
based therapy for CML.
For more information, please contact:
Anki Malmborg Hager, Investment director,anki(at)lubio.se, telephone
+46 768 28 48 22
Thomas Andersson, CEO,thomas(at)lubio.se, telephone +46 70 287 00 15
About LU Bioscience AB
Lund University Bioscience AB (LU Bio) was established to help satisfy the need
to transform high-end research results and innovations into attractive business
propositions through supporting researchers. LU Bio is an early-stage investor
who provides both capital and industrial development expertise to enable a fast
and efficient development of bioscience inventions.www.lubio.se
Press Release (PDF):
http://hugin.info/141955/R/1490414/426074.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: LU Bioscience via Thomson Reuters ONE
[HUG#1490414]
Unternehmensinformation / Kurzprofil:
Datum: 21.02.2011 - 09:00 Uhr
Sprache: Deutsch
News-ID 51733
Anzahl Zeichen: 3316
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cantargia builds power"
steht unter der journalistisch-redaktionellen Verantwortung von
LU Bioscience (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
